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Shiga toxin 1 elicits diverse biologic responses in mesangial cells.
Background. Shiga toxin 1 (Stx1) is a causative agent in hemo-
lytic uremic syndrome (HUS). Its receptor, the glycosphingolipid
globotriaosylceramide (Gb3), is expressed on cultured human
endothelial and mesangial cells. Mesangial cell injury in HUS
ranges from mild cellular edema to severe mesangiolysis and
eventual glomerulosclerosis. We hypothesized that, in addition to
endothelial cells, mesangial cells are targets of Stx1.
Methods. Human mesangial cells were exposed to Stx1. Protein
synthesis was measured using [35S]-methionine/cysteine. Cell via-
bility was measured as the lysosomal uptake of Neutral Red.
Monocyte chemotactic peptide (MCP-1) mRNA and protein were
analyzed by Northern blotting and ELISA.
Results. Stx1 (0.25 to 2500 ng/ml) resulted in a dose-dependent
inhibition of protein synthesis. This effect of Stx1 was potentiated
by preincubation of the cells with interleukin-1a (IL-1a; 2 ng/ml)
or tumor necrosis-a (TNF-a; 500 U/ml). Stx1 had little effect on
mesangial cell viability during the first 24 hours of exposure to
Stx1. However, prolonged incubation with Stx1 for 48 and 72
hours resulted in a 68% and 80% decrease in cell-viability,
respectively. Stx1 elicited a dose and time dependent increase in
the levels of MCP-1 mRNA, an effect that was potentiated by
preincubation with IL-1a.
Conclusion. These data indicate that mesangial cells are sus-
ceptible to the effects of Stx1 in vitro. Stx1 exerts a spectrum of
biologic effects on mesangial cells ranging from activation of
chemokine genes to a lethal toxic injury. Immunoinflammatory
cytokines potentiate the effects of Stx1. Thus, glomerular pathol-
ogy in HUS may also result from a direct effect of Stx1 on
mesangial cells.
Hemolytic uremic syndrome (HUS) consists of thrombo-
cytopenia, microangiopathic hemolytic anemia and acute
renal failure, and was first described in 1955 by Gasser et al
[1; reviewed in 2]. The disease is mostly seen in infants and
young children, but it can also affect older children or
adults, where the course often is more severe and associ-
ated with a higher incidence of complications. It is now
known that there is an association between HUS and
enteric infections with exotoxin producing bacteria, the
most common being verotoxin producing Escherichia coli
(VTEC) [3–5]. There are two types of verotoxins, also
known as Shiga toxins, Stx1 (VT1) and Stx2 (VT2). Both
toxins have been implicated in the pathogenesis of HUS.
Approximately 90% of all children with HUS show evi-
dence of VTEC infection, 70% of them with the E. coli
serotype O157:H7, which is known to produce Stx1 and
often Stx2 [6–8]. Both Stx1 and Stx2 consist of a 30 kD
A-subunit and five noncovalently associated B-subunits,
each about 7.5 kD [9]. The B-subunits are necessary for the
receptor binding of the whole toxin, which leads to inter-
nalization of the toxin/receptor-complex via clathrin coated
pits [10]. Within the cell, the subunits are dissociated and
the A-subunit inhibits cellular protein-synthesis by remov-
ing one nucleotide from the 28S ribosomal RNA of the 60S
ribosome subunit [11; reviewed in 12].
The functional receptor for Stx1, globotriaosylceramide
(Gb3), is a glycosphingolipid expressed on the cell mem-
brane [13, 14]. Gb3 has recently been identified in the
human kidney cortex and medulla and it is also highly
expressed on cultured human endothelial and mesangial
cells [15–21]. The number of Gb3 receptors found on the
cell membrane determines the susceptibility of the cells to
Stx1. It is thus not surprising that constitutive levels of Gb3
are about 50 times higher in human renal endothelial cells
(HRMEC), the most common target of Stx1, compared to
human umbilical vein endothelial cells (HUVEC) [20]. In
addition to endothelial cell injury, there is evidence of
mesangial cell involvement in HUS. In vitro and in vivo
studies indicate that mesangial cell injury contributes to
progressive nephrosclerosis. The spectrum of pathologic
changes involving mesangial cells in HUS ranges from mild
cellular edema to mesangiolysis. In severe cases, these
changes eventuate in glomerulosclerosis with irreversible
distortion of the glomerular architecture and loss of renal
function [22, 23].
Mesangial cell injury with consequent long-term effects
on kidney function and histopathology may result from the
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hypoxic/ischemic insult that follows primary endothelial cell
injury and the resulting thrombotic microangiopathy. How-
ever, it is also likely that Stx1 targets mesangial cells
directly, and that the effect of Stx1 on mesangial cells
contributes not only to the acute glomerular injury, but also
participates in the long-term complication of this disease.
In these studies, we investigated the biologic effects of Stx1
on human glomerular mesangial cells.
METHODS
Materials
Purified Stx1 was prepared as previously described [24].
Purified Stx1 migrated as two bands on SDS gel electrophore-
sis (30 kD and 7.5 kD), under reducing conditions. Purified
protein was suspended in 10 mM phosphate buffered saline
(PBS) at a concentration of 250 mg/ml (equivalent of 3.53 3
1026 M). Waymouth medium, modified Eagle’s medium with-
out methionine/cysteine, N-(2-hydroxyethyl)-piperazine-N9-
(2-ethanesulfonic acid) (HEPES), non-essential amino acids,
sodium pyruvate and human tumor necrosis factor-a (TNF-a)
were purchased from GIBCO (Grand Island, NY, USA).
Insulin, salmon sperm DNA, EDTA, sodium dodecyl sulfate
(SDS), trichloracetic acid, 3-amino-7-dimethylamino-2-meth-
yl-phenazine hydrochloride (Neutral Red), 5,6-dichloroben-
zimidazole-riboside (DRB) and sodium citrate (SSC) were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Glutamin, antibiotic/antifungal solution and fetal calf serum
(FCS) were from Atlanta Biological, Inc. (Norcross, GA,
USA). Human interleukin-1a (IL-1a) was from R&D Sys-
tems (Minneapolis, MN, USA). [3H]-thymidine, [32P]-dCTP
and intensifying screens were from DuPont NEN (Boston,
MA, USA). RNAzol was obtained from Tel-Test (Friends-
wood, TX, USA). [35S]-Trans-Label was from ICN (Irvine,
CA, USA). Megaprime kit was from Amersham (Arlington
Heights, IL, USA). CytElisa MCP-1 was from CYTImmune
Science, Inc. (College Park, MD, USA). X-OMAT AR X-ray
films were from Eastman Kodak (Rochester, NY, USA).
Cell culture
Cultures of human mesangial cells were established from
glomeruli isolated from human donor kidneys that were
unsuitable for transplantation or normal portions of surgi-
cal nephrectomy samples. These cells had been extensively
characterized by electron microscopy and immunohisto-
chemistry [25, 26]. The cells were free of epithelial or
endothelial contamination. Cells were used between the
sixth to tenth passages. Cells were maintained in Way-
mouth’s medium supplemented with 15 mM Hepes, 0.6
U/ml insulin, 2 mM glutamine, 100 mM nonessential amino
acids, 1 mM sodium pyruvate, antibiotic/antifungal solution
and 17% FCS. All assays were performed in triplicate or
quadruplicate.
Protein synthesis assay
Human mesangial cells were plated in 24-well dishes at a
density of 5 3 104 to 1 3 105 cells/ml in complete
Waymouth medium. Near confluent cells were washed with
PBS and preincubated in serum-free medium with or
without IL-1a [2 ng/ml] or TNF-a [500 U/ml] for 24 hours.
Stx1 was then added in concentrations ranging from 0.25
ng/ml to 2500 ng/ml for 1 to 72 hours. At the end of the
incubation, plates were washed twice with PBS to remove
the toxin and incubated in methionine/cysteine free MEM
containing 10 mCi/ml of [35S]-Trans-S-Label for three hours
at 37°C. The medium was then removed and the cells were
washed twice in PBS and twice in 10% trichloroacetic acid
on ice for 10 minutes each. Precipitated proteins were
solubilized by adding 0.7 ml of 5% SDS and 0.1 N NaOH for
15 minutes at room temperature on a shaking plate. 0.3 ml
of the precipitated radioactivity was neutralized with 50 ml
of 6 M HCl and counted in a liquid scintillation counter.
Results are expressed as percent protein synthesis in Stx1
treated cells compared with control non-treated cells.
Cytotoxicity assay
Human mesangial cells were plated in 24-well dishes at
the same density as the protein synthesis assay and grown
for 48 to 72 hours in complete Waymouth medium. The
cells were washed in PBS and preincubated in 1 ml
serum-free medium with or without IL-1a [2 ng/ml] for 24
hours. Then Stx1 in concentrations ranging from 0.25 to
250 ng/ml was added for 24 to 72 hours. One milliliter of
freshly diluted Neutral Red in PBS was added to a final
concentration of 50 mg/ml and cells were incubated for
additional two hours at 37°C. Cells were washed thoroughly
(4 times) with PBS to remove excess Neutral Red; then 0.5
N HCl in 35% ethanol was added for five minutes at room
temperature to release the dye from viable cells and the
absorbance in each well was quantitated in a spectropho-
tometer at 570 nm. Results are expressed as a percentage of
the absorbance of control cells or as optical density at 570
nm (OD570).
[3H]-thymidine assay
Human mesangial cells in 24-well dishes were rendered
quiescent by placing them for 24 hours in serum-free
medium containing IL-1a [2 ng/ml]. Fifteen percent of FCS
alone or with increasing doses of Stx1 ranging from 0.25 to
250 ng/ml was added for 24 hours at 37°C. Wells were then
washed with PBS and serum-free medium containing 25
mCi/ml [3H]-thymidine was added for four hours at 37°C.
Cells were then washed twice in 5% trichloracetic acid on
ice. Precipitated DNA was solubilized in 0.1% SDS and
0.25 N NaOH. Then, 0.3 ml of the precipitated radioactivity
was neutralized with 6 M HCl and counted in a liquid
scintillation counter. Results are expressed as cpm of
incorporated [3H]-thymidine.
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RNA isolation and Northern blotting
Human mesangial cells were grown in 100 mm Petri
dishes to near confluency. The medium was removed and
the cells were washed with PBS and then placed in serum-
free Waymouth medium with or without IL-1a (2 ng/ml).
After 24 hours, Stx1 (2.5 to 250 ng/ml), DRB (5 mg/ml) or
a combination of DRB and Stx1 was added for the time
periods as indicated. The cells were harvested by trypsiniza-
tion and total RNA was isolated by the modified method of
Chomczynski and Sacchi using RNAzol [27]. Twenty mi-
crograms of total RNA was electrophoresed through a
formaldehyde (1%) agarose gel and transferred overnight
to a GeneScreen membrane. A 715 bp EcoRI/NotI frag-
ment of baboon MCP-1 cDNA (kind gift of Dr. A. Valente)
was labeled with a-[32P]dCTP (5000 Ci/mmol) using the
Klenow fragment of E. coli [28]. As a control probe, a 114
bp RsaI fragment of human ribosomal RNA (36B4) was
also labeled. Prehybridization and hybridization were car-
ried out at 42°C in a buffer containing 50% formamide, 0.8
M NaCl, 0.02 M HEPES (pH 6.5), 20 mM EDTA, 100 mg/ml
denaturated salmon sperm DNA, and 0.5% SDS. After
hybridization, blots were washed twice in 2 3 SSC, 0.1%
SDS at 55°C for 15 minutes and finally in 0.5% SSC, 0.1%
SDS at 55°C for 20 minutes. The membranes were exposed
to x-ray film for 8 to 24 hours at 270°C with intensifying
screens. Variations in loading of RNA were tested by
ethidiumbromide staining and examination under UV light.
Monocyte chemotactic peptide-1 ELISA
Human mesangial cells were plated in 24-well plates at a
density of 2 3 104 cells/ml. Near confluent cells were
preincubated in serum-free medium overnight and then
Stx1 (1, 2.5 or 100 ng/ml) was added for 24 hours. Medium
was collected and centrifuged to remove cell debris and
stored at 220°C until assayed. The amount of human
MCP-1 protein was determined using a sandwich enzyme
immunoassay using a standard protocol provided by the
manufacturer (CYTImmune Science, Inc., College Park,
MD, USA). Samples were diluted 1:10 and 1:20 to ensure
that values fall within the linear range of the standard
curve. The sensitivity of the assay was 4.2 pg/ml with a
range of detection from 8 to 500 pg/ml.
Statistical analysis
Data shown are mean 6 SD. The unpaired t-test was used
to determine statistical significance with a two-tailed P
Fig. 1. Effect of Shiga toxin 1 (Stx1) on the
morphology of human mesangial cells in
culture. Cells were maintained without (A, C,
E) or with (B, D, F) Stx1 (250 ng/ml) for 24
hours (A, B), 48 hours (C, D) and 72 hours (E,
F). Cells were incubated in serum-free medium
in the presence of IL-1a (2 ng/ml) for 24 hours
prior to the addition of Stx1. Note the viable
cells after 72 hours of treatment with Stx1 (F).
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value of , 0.05 considered as significant difference be-
tween groups (Instat; GraphPad Software Inc., San Diego,
CA, USA).
RESULTS
Cell morphology
Figure 1 shows human mesangial cells incubated without
(A, C, E) or with (B, D, F) Stx1 for different time periods.
After 24 hours of Stx1 incubation, there are minimal
changes in cell morphology; few cells detach and some cell
blebbing can be seen. After 48 hours of Stx1 treatment
there is a clear reduction in cell number and the remaining
cells show an elongated shape and the cytoplasm starts to
become more reticulated. This is more visible after 72
hours exposure to Stx1, when few viable attached cells
remain.
Effect of Shiga toxin 1 on protein synthesis
Incubation of human mesangial cells with increasing
doses of Stx1 for 24 hours results in inhibition of protein
synthesis in a dose-dependent manner (Fig. 2A). This effect
was significant at concentration of 0.25 ng/ml of Stx1. A
60% inhibition was achieved at 2500 ng/ml Stx1. Preincu-
bation of the cells with 2 ng/ml IL-1a for 24 hours,
potentiated the inhibitory effect of Stx1 on protein synthe-
sis. Under these conditions, approximatly 60% inhibition
could be seen with doses of Stx1 as low as 2.5 ng/ml. A 90%
inhibition was achieved at 2500 ng/ml Stx1 (Fig. 2B).
Similar to the effect of IL-1a, incubation of mesangial cells
with TNF-a enhanced the inhibitory effect of Stx1 on
protein synthesis (Fig. 3).
Figure 4A shows the effect of cell density on the ability of
Stx1 to inhibit protein synthesis. Subconfluent cells are
more susceptible to the inhibitory effect of Stx1 than
confluent cells. A time course for the effect of Stx1 is shown
in Figure 4B. Within one hour of Stx1 treatment, protein
synthesis was inhibited by approximately 50%. Maximum
inhibition of 90% was achieved after 16 hours of Stx1
treatment. Longer incubations with Stx1 showed no further
inhibitory effect.
Effect of Shiga toxin 1 on cell viability
To evaluate if protein-synthesis inhibition in response to
Stx1 is associated with reduced cell viability, a Neutral Red
Fig. 2. Effect of Shiga toxin 1 (Stx1) on protein synthesis in human
mesangial cells. Protein synthesis was measured as the incorporation of
[35S]-methionine/cysteine into total protein. Cells were preincubated in
serum-free medium alone (A) or in the presence of IL-1a (2 ng/ml) (B) for
24 hours prior to the addition of increasing doses of Stx1 (0.25 to 2500
ng/ml) for 24 hours. Data are expressed as % of the controls which
represent cells incubated under the same conditions but without Stx1
(*two tailed P value , 0.05).
Fig. 3. Effect of cytokines on Stx1 induced inhibition of protein synthesis:
Protein synthesis was measured as the incorporation of [35S]-methionine/
cysteine into total protein of human mesangial cells. Cells were preincu-
bated in serum-free medium alone or in the presence of IL-1a (2 ng/ml)
or TNF-a (500 U/ml) for 24 hours prior to the addition of Stx1 (250 ng/ml)
for an additional 24 hours. Symbols are: (u) without Stx1; (f) with Stx1.
Data are expressed as percent and 100% represents the cells incubated
under the same conditions but without Stx1 (*two tailed P value , 0.05).
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assay was used to assess cell viability. For these studies,
cells were incubated under the same conditions as for the
protein-synthesis assay. Figure 5A shows that after 24 hours
of Stx1 incubation there is no significant reduction in the
number of viable human mesangial cells. After 48 hours of
Stx1 treatment, the number of viable cells was reduced to
35%, with further reduction in the number of viable cells to
25% after 72 hours. The cytotoxic effect of Stx1 on human
mesangial cells is dose-dependent (Fig. 5B). The minimum
concentration of Stx1 that resulted in significant cytotoxic-
ity was 0.25 ng/ml. At this concentration, Stx1 caused a 40%
reduction in viable cells. The highest concentration of Stx1
used was 2500 ng/ml and resulted in 85 to 90% reduction in
the number of viable cells. It is noteworthy that some cells
remained viable inspite of the high concentration of Stx1
and the prolonged incubation. This finding is in good
agreement with the time course of the effect of Stx1 on
protein-synthesis inhibition where some degree of protein
synthesis persisted after long-term Stx1 treatment, albeit at
a reduced level (Fig. 5). These data are also consistent with
the light microscopy studies showing attached viable cells
after 48 and 72 hours of Stx1 treatment (Fig. 1 C-F).
Effect of Shiga toxin 1 on DNA synthesis
Since mesangial cells are partially resistant to the cyto-
toxic effect of Stx1 compared to reported data on endothe-
lial cells, we next tested the effect of Stx1 on DNA synthesis
in human mesangial cells treated with serum. Treatment of
quiescent human mesangial cells with 15% fetal calf serum
resulted in a five- to sixfold increase in DNA synthesis. The
same response to 15% fetal calf serum was seen in cells
treated with increasing doses of Stx1 (Fig. 6). Thus, Stx1 at
concentrations that result in significant inhibition of pro-
tein synthesis did not alter DNA synthesis for at least 28
hours after exposure to Stx1. Only high concentrations of
Stx1 reduced DNA synthesis by about 20 to 25%.
Effect of Shiga toxin 1 on monocyte chemotactic peptide-
1 expression
We next tested the effect of Stx1 on MCP-1 mRNA
abundance and MCP-1 protein production. Basal levels of
Fig. 4. (A) Effect of cell density on Stx1
induced inhibition of protein synthesis. Human
mesangial cells were seeded at the indicated
densities in 12-well dishes and incubated in
serum-free medium in the presence of IL-1a (2
ng/ml) for 24 hours prior to the addition of
Stx1 (250 ng/ml) for an additional 24 hours.
Data are expressed as percent, and 100%
represents the cells incubated under the same
conditions but without Stx1. Symbols are: (u)
without Stx1; (f) with Stx1. (B) Time course
for the effect of Stx1 on protein synthesis in
human mesangial cells. Cells were preincubated
in serum-free medium in the presence of IL-1a
(2 ng/ml) for 24 hours prior to the addition of
Stx1 (250 ng/ml) for an additional 24 hours;
100% represents the cells incubated under the
same conditions but without Stx1 (*two tailed P
value , 0.05).
Simon et al: Shiga toxin 1 and mesangial cells 1121
MCP-1 mRNA in growth arrested human mesangial cells is
either undetectable or low. Treatment of mesangial cells
with Stx1 alone resulted in an increase of MCP-1 mRNA
abundance. This effect could be detected after 4 to 12 hours
of exposure to Stx1 and lasted for at least 24 hours.
Concentrations of Stx1 as low as 2.5 ng/ml increase MCP-1
mRNA abundance (Fig. 7A). We next tested the effect of
Stx1 on MCP-1 mRNA abundance in cells previously
exposed to IL-1a. Preincubation of mesangial cells with
IL-1a (2 ng/ml) for 24 hours resulted in an increase in
Fig. 5. (A) Time course for the effect of Stx1
on the uptake of Neutral Red into lysosomes of
human mesangial cells. Cells were
preincubated in serum-free medium in the
presence of IL-1a (2 ng/ml) for 24 hours prior
to the addition of Stx1 (250 ng/ml) for the
indicated time periods. Stx1 resulted in a time-
dependent decrease in the optical density (OD)
that represents the uptake of Neutral Red, a
measure of cell viability. Symbols are: (u)
without Stx1; (f) with Stx1. (B) Dose-response
relationship for the effect of Stx1 on the uptake
of Neutral Red into lysosomes of viable human
mesangial cells. Cells were incubated in serum-
free medium in the presence of IL-1a (2 ng/ml)
for 24 hours prior to the addition of Stx1 (0.25
to 2500 ng/ml) for an additional 48 hours. Data
are expressed as percent. 100% represent cells
incubated under identical conditions but
without Stx1 (*two tailed P value , 0.05).
Fig. 6. Effect of Stx1 on DNA synthesis. DNA
synthesis was measured as the incorporation of
[3H]-thymidine into TCA precipitable material.
Human mesangial cells were incubated in
serum-free medium in the presence of IL-1a (2
ng/ml) for 24 hours prior to the addition of
15% fetal calf serum with or without increasing
doses of Stx1 (*two tailed P value , 0.05).
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MCP-1 mRNA expression. The addition of Stx1 to cells
preincubated with IL-Ia caused a further increase in
MCP-1 gene expression (Fig. 7B). The rapid increase in
MCP-1 mRNA abundance in response to Stx1 suggest a
transcriptional mechanism of regulation. Coincubation of
mesangial cells with Stx1 and the transcription inhibitor
DRB (5 mg/ml) prevented the increase of MCP-1 mRNA
abundance by Stx1 (Fig. 7C). These data suggest that Stx1
induced MCP-1 gene induction is due to enhanced MCP-1
mRNA transcription. Concomitant to the increase in MCP-
mRNA abundance, the levels of MCP-1 protein measured
by an ELISA increased significantly from 11.96 6 1.95 to
18.04 6 1.04 ng/ml (control vs. Stx1 2.5 ng/ml). This
increase in MCP-1 protein was dose-dependent starting
with a Stx1 concentration as little as 1 ng/ml (Fig. 8).
DISCUSSION
This study demonstrates that mesangial cells, which are
commonly involved in the histopathologic manifestations of
HUS, are direct targets of Stx1 and that Stx1 exerts diverse
biologic effects on these cells. Stx1 inhibits protein-synthe-
sis of human mesangial cells in a dose- and time-dependent
manner. The proinflammatory cytokines IL-1a and TNF-a
markedly potentiate the inhibitory effect of Stx1. In spite of
the rapid and significant inhibition of protein synthesis,
Stx1 elicited no short term cytotoxic effect on mesangial
Fig. 7. Induction of MCP-1 mRNA in human
mesangial cells by Stx1. Cells were plated in
100 mm dishes and grown to near confluency.
(A) Cells were preincubated for 24 hours in
serum-free medium prior to the addition of
increasing concentrations of Stx1 for the time
periods indicated. (B) Cells were preincubated
with IL-1a (2 ng/ml) for 24 hours prior to the
addition of Stx1 (2.5 ng/ml) for the time
periods indicated. RNA was analyzed by
Northern blotting (Methods section) using a
baboon MCP-1 cDNA. Lower two panels show
the result of hybridization of the same blot with
36B4 cDNA as a housekeeping gene and the
ethidium bromide staining of the membranes
after RNA transfer. (C) Inhibition of Stx1
induced MCP-1 mRNA by the transcriptional
inhibitor DRB. Human mesangial cells were
plated in 100 mm dishes and grown to near
confluency. Cells were preincubated in serum-
free medium for 24 hours prior to the addition
of Stx1 (2.5 ng/ml), DRB (5 mg/ml) or both.
RNA was analyzed by Northern blotting using a
baboon MCP-1 cDNA. Lower two panels show
the result of hybridization of the same blot with
36B4 cDNA and the ethidium bromide staining
of the membrane after RNA transfer.
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cells. However, prolonged exposure of the cells to Stx1
results in significant cytotoxicity. Stx1, under conditions
that do not result in significant protein synthesis inhibition
or cytotoxity, induces the expression of MCP-1 gene and
protein.
The pathophysiology of HUS is not yet fully elucidated.
While damage to the endothelium of the human kidney is
thought to be the primary event in this disease, the factors
that determine the severity of the acute injury as well as the
long-term outcome are not known. The discovery of a
bacterially-derived toxin as a major cause of HUS exerting
its effect on a naturally occurring specific receptor primarily
expressed on endothelial cells helped elucidate some of the
pathogenic mechanisms of HUS. Microvascular endothelial
injury results in a microthrombotic angiopathy that leads to
a variable degree of renal ischemia. The presence of a
specific ligand-receptor mediated process indicates that the
injury to other renal cells may not simply result from a
passive standby damage consequent to the ischemia. If
other cells of the kidney, particularly cells that contribute to
the histopathologic manifestations of the disease, are sus-
ceptible to the effect of Stx1, such an effect most likely
represent a direct receptor-mediated action. Mesangial
cells express the receptor for Stx1 [29], and our studies
indicate that Stx1 exerts multiple biologic effects in these
cells. Protein synthesis in mesangial cells is inhibited by
Stx1 at concentrations in the picomolar to nanomolar
range. These concentrations are somewhat higher than
those required to inhibit protein synthesis in HRMEC. In
the presence of cytokines, concentrations of Stx1 that are
required to inhibit mesangial cell protein synthesis are
comparable to those effective in HRMEC [20, 30]. On the
other hand, HUVEC do not respond to Stx1 unless they are
primed with immune inflammatory cytokines [20, 31].
These data provide evidence that human mesangial cells
similar to HRMEC are much more susceptible to protein
synthesis inhibition by Stx1 than HUVEC, a non renal
endothelial cell line. Immune inflammatory cytokines also
potentiate the effects of Stx1 on mesangial cells. Pretreat-
ment of mesangial cells with IL-1a or TNFa increases their
susceptibility to the effects of Stx1 to a level that approxi-
mates the response of HRMEC. Interestingly, these two
cytokines also markedly alter the time course kinetics of
mesangial cell response. These data indicate that the
susceptibility of mesangial cells to the effect of the toxin is
dependent on the availability of cytokines in the microen-
vironment. It should be emphasized that rather high con-
centrations of cytokines released by activated monocytes or
macrophages can be achieved locally in the vicinity of
mesangial cells.
Human mesangial cells are also more susceptible to the
cytotoxic effects of Stx1 than HUVEC and are almost as
susceptible as HRMEC. In HRMEC, Stx1 is cytotoxic at
femtomolar range, concentrations that do not inhibit pro-
tein synthesis. On the other hand, HUVEC are susceptible
at nanomolar concentrations and only after exposure to
immune inflammatory cytokines [20]. We find that pro-
longed exposure of mesangial cells to Stx1 is required
before significant cytotoxicity can be demonstrated. It is
interesting to note that, in spite of significant inhibition of
protein synthesis in response to Stx1, mesangial cells con-
tinue to synthesize DNA when incubated in the presence of
serum. Only at high concentrations does Stx1 result in a
small inhibition of DNA synthesis. Collectively, the data
suggest that the differential response of the cells to Stx1 in
terms of cell viability may be related to differential effects
on protein synthesis. Recent evidence indicates that cell-
specific responses to Stx1 are not necessarily dependent on
the number of Gb3 receptors. The type of cell surface
glycolipids and length of fatty acid chain as well as the
activity of specific intracellular lipid metabolizing enzymes
are major determinants of the nature and severity of the
biologic response of cells to Stx1 [32–37].
Van Setten et al have recently reported that Stx1 inhibits
protein synthesis in human mesangial cells [38]. The con-
centrations required to inhibit protein synthesis (0.1 to 10
nmol/liter) was similar to the concentrations we used.
However, the authors found that Stx1 does not decrease
cell viability even after prolonged incubation in serum
containing medium. It is likely that serum prevents or
minimizes cytotoxicity since our viability assays were per-
formed in the absence of serum. It is noteworthy that
similar to their observation, we find that Stx1 inhibits
protein synthesis even in the presence of serum (data not
shown). It is likely, as van Setten et al suggested, that
protein synthesis inhibition can be largely dissociated from
cell viability; also of note is that they did not find that
Fig. 8. Increased production of MCP-1 by Stx1 in human mesangial cells.
Cells were grown to near confluency in 12-well plates. Cells were
preincubated in serum-free medium for 24 hours prior to the addition of
Stx1 in the indicated concentrations. The medium was collected after 24
hours, centrifuged and diluted in PBS (1:20) for measurement of MCP-1
by the sandwich ELISA technique.
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preincubation with cytokines potentiates the cytotoxicity
induced by Stx1.
Mesangial cells are a known source for MCP-1, a che-
mokine involved in a variety of glomerular inflammatory
diseases due to its chemoattractant effect on monocytes
and lymphocytes [39–41]. Infiltration by inflammatory
cells, particularly monocytes, is now a recognized manifes-
tation of HUS [22, 42]. We now demonstrate that Stx1
increases MCP-1 mRNA abundance and that this effect is
potentiated in the presence of cytokines. The rapid in-
creases in MCP-1 mRNA levels which can be prevented by
DRB suggest a transcriptional mechanism of activation by
Stx1. These data are at variance with a recent report
demonstrating lack of effect of Stx1 on chemokine produc-
tion [38]. These differences may be related to different
responses of separate cell isolates to Stx1, or to the use of
serum that can maximally activate the cells and render
them unresponsive to Stx1. Activation of mesangial cells by
Stx1 in HUS and production of MCP-1 may be responsible
at least partially for the infiltration of peripheral blood
mononuclear cells into the kidney. Monocytes may be
activated by MCP-1 to produce cytokines including IL-1
and TNF-a, which in turn may enhance the effects of Stx1
on its renal target cells in HUS. It has been shown in a
mouse model of HUS that the kidney is the sole source of
excessive TNF-a production [43]. The specific cell type that
produces TNF-a within the kidney is unknown, but the
authors speculated that incoming monocytes/macrophages
might be the source of TNF-a. This hypothesis is strength-
ened by findings in C3H/HeJ mice whose monocyte/mac-
rophage function is deficient. These mice show a signifi-
cantly longer mean time to death compared to normal
controls when treated with lethal doses of Stx1 [44].
Furthermore, it has been demonstrated that human mono-
cytes treated with Stx1 produce high amounts of TNF-a in
vitro [45, 46].
While extrapolation from in vitro to in vivo data should
be cautious, our studies suggest that activation of mesangial
cells by Stx1 may be relevant to progressive renal injury that
results from HUS. Activation of mesangial cells is one
major factor that results in glomerulosclerosis [47]. Indeed,
despite partial recovery of renal function in HUS, progres-
sive glomerulosclerosis with or without segmental or diffuse
mesangial proliferation in remaining glomeruli is a well
recognized long-term complication [23, 48]. In studies
looking at the outcome of kidney function ten years after
Fig. 9. Schematic hypothesis of the effect of
Stx1 on human mesangial cells in HUS. Details
are in the text.
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HUS, only 60% of the patients showed normal kidney
function [49, 50]. Moreover, only 40% of the patients
showed no renal abnormalities 15 to 25 years after HUS
[51]. Our studies indicate that mesangial cells are relatively
resistant to the cytotoxic effect of Stx1 unless the cells were
exposed to immune inflammatory cytokines. Therefore, the
severity and the duration of exotoxemia and consequent
release of cytokines may play an important role in the
outcome of the glomerular lesion in HUS, that is, complete
resolution or sclerosis with residual impairment of renal
function. The circulating or tissue levels of Stx1 are un-
known. Concentrations of Stx1 that cause endothelial cell
lysis may result in mesangial cell activation with subsequent
production of MCP-1 and other cytokines. It is not difficult
to conceptualize how Stx1 gains access to the mesangium.
Mesangial cells may be exposed to plasma constituents and
even more so after lysis of endothelial cells, the only barrier
between blood circulating in the glomerular capillaries and
the mesangium. Mesangial cell activation or injury may also
be initiated or potentiated by material released upon
endothelial cell injury or lysis. Activation of mesangial cells
in vivo may be responsible for the incomplete resolution of
glomerular lesions and the development of glomeruloscle-
rosis observed in severe cases of HUS. A schematic illus-
tration of this hypothesis is shown in Figure 9.
These data provide evidence that in addition to endothe-
lial cells, human mesangial cells are susceptible to the
effects of Stx1 in vitro. Stx1 exerts a spectrum of biologic
effects in mesangial cells ranging from induction of chemo-
kine expression to marked inhibition of protein synthesis
and cytotoxicity. Glomerular pathology and long-term com-
plications of HUS may therefore result from a direct effect
of Stx1 on mesangial cells in addition to its effects on
endothelial cells.
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APPENDIX
Abbreviations used in this article are: DRB, 5,6-dichlorobenzimidazole-
riboside; Gb3, glycosphingolipid globotriaosylceramide; HEPES, N-(2-
hydroxyethyl)-piperazine-N9-2-ethanesulfonic acid; HRMEC, human re-
nal endothelial cells; HUS, hemolytic uremic syndrome; HUVEC, human
umbilical vein endothelial cells; IL-1a, interleukin-1a; MCP-1, monocyte
chemotactic peptide; SDS, sodium dodecyl sulfate; SSC, sodium citrate;
STX1 and STX2, Shiga toxin 1 and 2; TNF-a, tumor necrosis factor-a;
VTEC, verotoxin producing Escherichia coli.
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